Sunway Group’s Post

Malaysia's healthcare industry faces significant challenges, including a shortage of skilled workers, insufficient R&D investment, and technological gaps, especially in rural areas. However, the pharmaceutical sector is advancing, supported by robust government policies that promote local manufacturing and international collaborations. Join us at our Malaysian Healthcare Industry Outlook where we will explore Malaysia's current developments and its potential to emerge as a key player in the highly competitive ASEAN healthcare market. 📅: Friday, 4 October 2024 🕙: 10.00 am – 12.00 noon 📍: Harmony Hall, Tower D, Sunway Medical Centre, Subang Jaya, Selangor Invited panellists: • Dr Rabindra Abeyasinghe, Representative to Malaysia, Brunei Darussalam and Singapore, World Health Organisation (WHO) • Dr Seow Vei Ken, Chief Executive Officer, Sunway Medical Centre, Sunway City • Pixie Yee, Managing Director of Merck Malaysia and General Manager of Merck Healthcare Malaysia and Singapore • Zuaida Abdullah, Executive Director, Services Development, Malaysian Investment Development Authority (MIDA) To register for the outlook, please visit https://loom.ly/bvewWN0 #MGCCEvents #PartnerInMalaysia #HealthcareInnovation #MalaysiaHealthcare #HealthTech #RuralHealthcare #HealthcareResilience #PharmaceuticalIndustry #GlobalHealth

Dear Business Partners/ Associates / Stakeholders,   Clinical Research Malaysia is expanding in its business as we experience an increased volume of trials in the country. The business expansion has become inevitable due to the growth of sponsored research in the region and with Malaysia seen as a favorable site for multi-regional clinical trials. As the result, we need to re-organize our Clinical Operations aiming at enhancing our business and operational effectiveness and efficiency in providing services, delivering clinical trials to customers. The business expansion which leads to the re-organization of Clinical Operations is effective 18 September 2024.   The re-organization is demonstrated with the expansion of regions from 10 to 15 coming with opportunities for career growth of 5 new Associate Regional Managers. This re-organization is also in line with CRM’s mission in human capital development   We are confident that this re-organization will boost our focus on operational excellence with speed, quality and reliability practiced consistently throughout Clinical Research Malaysia.   Together, we work hand in hand to achieve our missions synchronized and guided by our guiding principles of Humanity, Stability and Sustainability.   We appreciate every cooperation and support of all our customers, business partners/associates, and stakeholders in making this significant transition a great success!   From the Management of Clinical Research Malaysia Click link to read more! https://lnkd.in/gBAaWMYU #clinicalresearchmy #advancingclinicalresearch #askusaboutclinicalresearch

Just in: Asia Specials: The Top 3 Best Places to Work in Indonesia for 2023 revealed: JAKARTA, INDONESIA – Media OutReach Newswire – 5 January 2024 – Novo Nordisk, AstraZeneca and Darya-Varia Laboratoria are recognized as the top 3 best places to work in Indonesia for 2023 according to the annual prestigious “Best Places to Work” certification program. Best Places to Work is an international certification program, considered as the ‘Platinum Standard’ in identifying and recognizing top workplaces around the world, providing employers the opportunity to learn more about the engagement and the satisfaction of their employees and honour those who deliver an outstanding work experience with the highest standards in regards to working conditions. Novo Nordisk Indonesia, an affiliate of the global healthcare company with more than 100 years of innovation and leadership in diabetes care, was awarded the top position followed by AstraZeneca Indonesia, an affiliate of the multinational pharmaceutical and biopharmaceutical company. Darya-Varia Laboratoria, a pharmaceutical company engaged in the manufacture and the trade of pharmaceutical products and cosmetics, came in the third position. Despite the challenges faced globally around employee turnover and declining engagement level, the average level of engagement of the top performing companies in Indonesia is 85% and this is something to be proud of. This achievement not only demonstrates the ongoing commitment of those employers to building and sustaining an open and transparent work environment, but also their efforts in keeping business engagement firmly rooted in trust, ethics, and behaviors. Every year in Indonesia, the program partners with many organizations, across different industries, to help them measure, benchmark, improve their HR practices and use data-driven insights to add value, enhance agility, and increase organizational effectiveness. For more information about the program, please visit https://lnkd.in/e4W39Gq. Join our community on LinkedIn, Twitter, and Facebook. Hashtag: #BestPlacesToWorkFor The issuer is solely responsible for the content of this announcement. via The Top 3 Best Places to Work in Indonesia for 2023 revealed

Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company. As we continue to globalise we recognise that developing a Global Mindset is critical to our corporate core values of Teamwork and Innovation and the future growth of our Company. The Kyowa Kirin Global Exchange Programme (GEP) assigns talents selected through open application to different Kyowa Kirin Regions as a short-term assignment for on-the-job training for a period of three months. The programme this year took place between September - November 2023 and we plan to conduct this programme annually. 6 Candidates were assigned to both Kyowa Kirin in Tokyo, Japan and Kyowa Kirin International in Marlow, UK. Candidates were selected by free application to the programme and screening and interview with Host Line Manager. The objective of the programme is to strengthen and develop our global talent to deliver life-changing value, foster a culture where employees take on challenges, and support their autonomous career building. The GEP aims to provide opportunities for development of talents with a global mindset who are appropriate to a Japan-based Global Specialty Pharmaceutical Company; and to encourage participants to acquire practical work experience, expertise, adaptability to foreign culture, and personal network through on-the-job training in another country. The programme facilitated the creation of global networks that transcended geographical boundaries. Participants, once strangers, are now interconnected through the memories, experiences, and challenges they faced together. These networks will continue to flourish even as the programme comes to an end, serving as a testament to the enduring impact of this initiative. In the final presentations of all 6 participants, we heard from them individually and their Host Line Managers the impact their work and the GEP has had on various teams and initiatives throughout Kyowa Kirin. We heard about the learnings from professional and personal perspectives and how these global experiences have brought a new lens and view of what working in Kyowa Kirin means. It has been a pleasure to work on such an impactful talent development programme, and I’m already looking forward to what 2024 will bring! A BIG thank you to the dedicated Global HR Team without whom this would never be possible. #GlobalMindset #TalentExchange #KyowaKirin #Teamwork #Innovation #pharmaceuticalindustry Matt Pradhan Sakurako N. Fuyuko Sato Kunii Daisuke Matt Dreesden Alexandria McGrath, SHRM-CP Etsuko Takagi

Headlining this week's CHC Newsflash: Japanese-based Mitsui & Co., Ltd. and ROHTO Pharmaceutical Co., Ltd. are close to acquiring a majority stake in Eu Yan Sang, according to Bloomberg, citing people familiar with the matter. In 2023, Bloomberg reported that a consortium led by Singapore’s Tower Capital Asia, which includes investment company Temasek and members of the founding family, were considering the sale of a majority stake in the TCM health & wellness company, valued at around US$800mn. Established more than 140 years ago and with its HQ in Singapore, Eu Yan Sang has an extensive distribution network, with 170+ retail outlets in the APAC region.   I've been a fan of this business since Richard Eu Yee Ming, the chairman of the company, gave a wonderful presentation at our very first Asia conference, held in Beijing almost 30 years ago. Eu Yan Sang began as a Chinese medical business in Malaysia more than 140 years ago and branched out to Hong Kong and then Singapore, where it is now headquartered. Those were the days! Richard and his team have updated the products and stores, skilfully balancing all that's good about TCM with a more modern approach to marketing and retailing. Not least, he and two cousins bought the business back from the third party to whom the 3rd generation of the Eu family had sold it. And now two leading Japanese companies are interested in taking this business over for a very substantial premium. Rohto is another company I admire and the chemistry between the various companies — assuming this deal goes ahead — and the wider availability of the Eu Yan Sang brand, should be magical.   Although there are similarities, TCM is by no means the same as VMS, so it is interesting to see that VMS is staging a revival in the Asia-Pacific region, as evidenced by CHC Insight Asia-Pacific's recent review of the category and the most recent trading results from by By-Health and Health & Happiness . As the CHC industry struggles to achieve organic growth, it is reassuring that its biggest sector by far in Asia-Pacific is scaling new heights. To read more of my thoughts on this and other key CHC headlines and developments, trial our combined news service by contacting Melissa #consumerhealthcare #CHC #CHCNewsflash #CHCNewDirections #Japan #AsiaPacific #Matsui #Rohto #EuYanSang #TCM #China #VMS

Next step in Asia – we enter into a new agreement with First Pharma in Malaysia and Brunei As the Asia-Pacific-Region (APAC) consists of more than 4.3 billion citizens and offers dynamically growing economies, we have the target to accelerate growth in Asia and make the most eastern part a significant contributor to our business. Today we made our first step by signing our first new Marketing and Distribution Agreement with First Pharma from Malaysia for the distribution of one of our flagship products. We expect this to be the first step in a long-lasting partnership, as we will add further products to the portfolio. Therefore, Patrick Tichy, Business Partner Manager for Southeast Asia, and Magnus Kuester, Head of Region APAC, met with Tony Tam, Business Development Director and Partner of First Pharma, in London, to put pen to paper and seal our collaboration and discuss about future endeavors. We are excited and looking forward to this new business cooperation! #AsiaExpansion #BusinessPartnership #FirstPharma #MalaysiaBusiness #BruneiBusiness #APACGrowth #DistributionAgreement #SoutheastAsia #NewOpportunities #GlobalExpansion

Congratulations to the top 3 #workplaces in #indonesia for 2023. Novo Nordisk #indonesia achieved the first position followed by AstraZeneca indonesia. PT Darya - Varia Laboratoria Tbk achieved the #third position. Findings from this year indicated that the #top #performing organizations in #indonesia continued to invest in creating a highly-#engaged #workforce, with an average #engagement score of 85%, 4 points higher compared with the region average #engagement score. #bestplacestowork2023 #bestplacestoworkinindonesia #bestcompaniestoworkfor #culture #engagement

"Going through the (Top Employers) certification process has been one of the most impactful decisions our organisation has ever made," says Valerie Ann Valeza, MBA of HR at Fresenius Kabi Philippines. We recently had the opportunity to speak with Valerie for an exclusive interview, during which she shared invaluable insights into their journey to becoming a Top Employer. She discussed the significance of this recognition and shed light on the innovative initiatives and programs that contributed to their certification. Watch the full interview here: https://ow.ly/YmTJ50Ra7Ox #TopEmployers #TopEmployers2024

🌐 Navigating the Future of Clinical Trials in Indonesia Indonesia stands at the cusp of a significant leap forward in the global clinical trials landscape. With a wealth of biodiversity and a burgeoning healthcare sector, the potential for growth and innovation is immense. However, realizing this potential hinges on Indonesia's ability to refine the processes that underpin research collaborations. Material Transfer Agreements (MTAs) are pivotal in this regard, serving as the cornerstone for the ethical and legal transfer of research materials. To enhance Indonesia's competitive edge and foster a more conducive environment for international research partnerships, we must address key areas within our MTA framework: 🔑 Key Recommendations: 1️⃣ Streamlining Regulatory Processes through Digitalization for Timely Approvals: A centralized digital platform could be the gateway to reducing approval times for MTAs, ensuring Indonesia can meet the fast-paced demands of global clinical trials. 2️⃣ Harmonization with International Standards and Digital Compliance: Digital tools can help to synchronize Indonesia's MTA protocols with global benchmarks, solidifying its standing as a compliant and forward-thinking research hub. 3️⃣ Public Transparency and Digital Engagement: Leveraging digital platforms for public consultation and engagement can build trust and foster an inclusive research ecosystem, crucial for the ethical expansion of clinical trials in Indonesia. Embracing these recommendations could revolutionize how MTAs are managed, propelling Indonesia to the forefront of international clinical research. It's time for strategic digital innovation in our regulatory processes, aligning our aspirations with global standards and practices. #ClinicalTrials #IndonesiaHealthcare #DigitalInnovation #RegulatoryReform #GlobalCollaboration #MTA

We are thrilled to share that our team recently had a fruitful meeting with representatives from Vietnamese manufacturers, alongside Aleph India! 🇮🇳🤝🇻🇳 We discussed strategies to enable smoother business operations in India and gain deeper insights into the country's regulatory compliance requirements, particularly focusing on BIS certification. This collaboration opens up exciting opportunities for both sides, paving the way for enhanced market presence and streamlined processes. Stay tuned for more updates as we continue to forge ahead together! 💼💡 #BusinessExpansion #Collaboration #RegulatoryCompliance